A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study

Nicole J. Ullrich, Mark W. Kieran, Bruce R. Korf et al.|Neuro-Oncology|2020

Cited by 82